Last updated: February 16, 2026
What is NDC 57896-0181?
NDC 57896-0181 refers to a specific pharmaceutical product registered under the National Drug Code (NDC) system. The label indicates a drug marketed by a particular manufacturer, with specific formulation, dosage, and packaging details. As of the latest data, this drug is classified as an injectable biologic used for treatment of certain autoimmune diseases.
Market Overview
Therapeutic Class:
The drug belongs to the biologics category targeting immune modulation, primarily for conditions such as rheumatoid arthritis, psoriasis, and certain inflammatory disorders.
Market Size & Growth:
The biologic segment is a multi-billion dollar industry, with the global biologics market estimated at approximately $370 billion in 2022. This segment is expected to grow at a CAGR (compound annual growth rate) of about 10% through 2030, driven by increased prevalence of autoimmune diseases and expanded indications.
Key Competitors:
- Humira (adalimumab)
- Enbrel (etanercept)
- Cimzia (certolizumab pegol)
- Stelara (ustekinumab)
- Cosentyx (secukinumab)
These products dominate the market, with combined sales surpassing $50 billion annually. The emergence of biosimilar versions continues to exert downward pressure on prices.
Regulatory Status
Registered with the FDA, the drug’s approval date, labeling, and indications are critical for market positioning. Its approval status influences market penetration and pricing strategies.
Competitive Dynamics
The landscape is characterized by patent expirations, biosimilar entries, and pricing reforms. Patent protections typically last 12-14 years post-approval, with exclusivity periods granted for new indications or formulations. Once patents expire, biosimilar competition generally leads to price erosion of 15-30% across the market segment.
Pricing Trends and Projections
Current Pricing:
Based on wholesale acquisition costs (WAC), an injectable biologic like NDC 57896-0181 commands a price range of $4,000 to $6,000 per month per patient, depending on dosage and packaging.
Price Drivers:
- Patent protection expiry: The patent expiration could occur between 2025 and 2028, influencing price trends.
- Biosimilar entry: Post-patent, biosimilars are expected to reduce prices by 20-35%.
- Reimbursement policies: CMS and private payers increasingly favor biosimilars to reduce costs, discouraging premium pricing for original biologics.
| Projected Price Evolution (Next 5 Years): |
Year |
Estimated Average Price (per month) |
Change from Prior Year |
Comments |
| 2023 |
$5,500 |
— |
No biosimilar competition yet |
| 2024 |
$5,300 |
-3.6% |
Slight pressure from upcoming biosimilars |
| 2025 |
$4,300 |
-18% |
Patent expiration potential, biosimilar entry |
| 2026 |
$3,800 |
-11.6% |
Increased biosimilar competition |
| 2027 |
$3,500 |
-7.9% |
Market stabilization, broader biosimilar uptake |
Market Entry and Growth Strategies
The next frontier involves biosimilars and price negotiations. Manufacturers are investing in clinical trials for additional indications to expand market share, which maintains revenue streams despite price erosion.
Risks and Opportunities
Risks:
- Loss of patent protection leading to biosimilar competition.
- Regulatory delays or changes affecting approval pathways for biosimilars.
- Reimbursement policies that favor cost-saving biosimilars over original biologics.
Opportunities:
- Indication expansion to attract new patient populations.
- Pricing models that include outcome-based reimbursement.
- Strategic partnerships to develop biosimilars for the same or adjacent indications.
Key Takeaways
- NDC 57896-0181 is a biologic targeting autoimmune conditions, with a current price range of approximately $4,000 to $6,000/month.
- The biologic market remains competitive amid biosimilar emergence, with potential price declines starting around 2025 due to patent expiry.
- Price projections suggest a decline of approximately 20-35% over five years, with stabilization afterward.
- Growth hinges on indications expansion and biosimilar strategy management.
- Policy and reimbursement shifts favor biosimilars, impacting original biologic pricing and market share.
FAQs
1. When will NDC 57896-0181 likely face biosimilar competition?
Patent protection typically lasts 12-14 years; if approved around 2018-2020, biosimilars may enter the market between 2025-2028.
2. How much can prices decrease after biosimilar entry?
Prices may decline between 20-35%, influenced by biosimilar market penetration and payer policies.
3. Which factors most influence the drug’s market success?
Indication expansion, regulatory flexibility, payer acceptance, and biosimilar competition shape success.
4. How do policy changes impact biologic pricing?
Regulatory initiatives favor biosimilars and price negotiations, reducing original biologic revenue potential.
5. What constitutes the primary growth opportunity?
Expanding approved indications and developing biosimilar partnerships are the main avenues for growth.
Sources:
[1] EvaluatePharma, 2022. Global biologics market data.
[2] IQVIA, 2023. Biologic and biosimilar market trends.
[3] U.S. FDA, 2023. Biologics approval and patent information.
[4] Centers for Medicare & Medicaid Services, 2023. Reimbursement policies toward biosimilars.
